The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2024

Filed:

Mar. 05, 2018
Applicant:

New York University, New York, NY (US);

Inventors:

Daniel Meruelo, Scarborough, NY (US);

Alicia Hurtado Martinez, New York, NY (US);

Christine Pampeno, New York, NY (US);

Iris Scherwitzl, Hoboken, NJ (US);

Assignee:

New York University, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C12N 15/86 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C12N 2770/36133 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36143 (2013.01); C12N 2770/36171 (2013.01);
Abstract

Provided are polynucleotides and viral vectors, e.g., alphavirus or Sindbis viral vectors, encoding multiple, e.g., two or more, epitopes of at least one tumor associated antigen, in which each epitope is separated by a processing or enzyme cleavage site. The encoded epitopes may be the same or different. Also provided are polynucleotides and viral vectors, particularly, alphavirus or Sindbis viral vectors, encoding an immune checkpoint protein, or a ligand binding portion thereof. The immune checkpoint protein or ligand binding portion thereof may be fused to immunoglobulin domains, e.g., an Ig hinge domain and an Ig heavy chain constant domain. Methods of treating subjects having a cancer or tumor, e.g., a TAA-expressing tumor, with the described viral vectors are provided. Treatment of subjects with the vectors, the checkpoint inhibitor molecules and/or other immunomodulatory components, generate an anti-cancer or anti-tumor immune response resulting in increased survivability of tumored subjects and epitope spreading.


Find Patent Forward Citations

Loading…